These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8617582)
1. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. Gradishar WJ; Vogelzang NJ; Kilton LJ; Leibach SJ; Rademaker AW; French S; Benson AB Invest New Drugs; 1995; 13(2):171-4. PubMed ID: 8617582 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of echinomycin in advanced soft tissue sarcomas. A Southwest Oncology Group study. Taylor SA; Metch B; Balcerzak SP; Hanson KH Invest New Drugs; 1990 Nov; 8(4):381-3. PubMed ID: 2084072 [TBL] [Abstract][Full Text] [Related]
3. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM; Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685 [TBL] [Abstract][Full Text] [Related]
4. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma. Pazdur R; Samson MK; Baker LH Am J Clin Oncol; 1987 Jun; 10(3):237-9. PubMed ID: 3473924 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185 [TBL] [Abstract][Full Text] [Related]
6. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of piperazinedione in metastatic sarcoma. Presant CA; Bartolucci AA Am J Clin Oncol; 1982 Apr; 5(2):185-7. PubMed ID: 7046413 [TBL] [Abstract][Full Text] [Related]
8. Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group. Muss HB; Blessing JA; Baker VV; Barnhill DR; Adelson MD Am J Clin Oncol; 1990 Aug; 13(4):299-301. PubMed ID: 2198794 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of elliptinium in metastatic soft tissue sarcoma. Somers R; Rouësse J; van Oosterom A; Thomas D Eur J Cancer Clin Oncol; 1985 May; 21(5):591-3. PubMed ID: 4007025 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study. Brown TD; Goodman PJ; Fleming TR; Taylor SA; Macdonald JS Invest New Drugs; 1991 Feb; 9(1):113-4. PubMed ID: 2026480 [No Abstract] [Full Text] [Related]
11. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion. Kuhn JG; Von Hoff DD; Hersh M; Melink T; Clark GM; Weiss GR; Coltman CA Eur J Cancer Clin Oncol; 1989 May; 25(5):797-803. PubMed ID: 2737217 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study. Marshall ME; Wolf MK; Crawford ED; Taylor S; Blumenstein B; Flanigan R; Meyers FJ; Hynes HE; Barlogie B; Eisenberger M Invest New Drugs; 1993; 11(2-3):207-9. PubMed ID: 8262733 [TBL] [Abstract][Full Text] [Related]
14. Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group. Bochennek K; Dantonello T; Koscielniak E; Claviez A; Dirksen U; Sauerbrey A; Beilken A; Klingebiel T Klin Padiatr; 2013 Nov; 225(6):309-14. PubMed ID: 23946091 [TBL] [Abstract][Full Text] [Related]
15. [A pilot study of high-dose zorubicin in advanced stages of soft tissue sarcoma in adults]. Jelić S; Tomasević Z; Kreacić M; Kovcin V; Radosavljević D; Vlajić M Bull Cancer; 1996 Dec; 83(12):1002-7. PubMed ID: 9116363 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641. Schilsky RL; Faraggi D; Korzun A; Vogelzang N; Ellerton J; Wood W; Henderson IC Invest New Drugs; 1991 Aug; 9(3):269-72. PubMed ID: 1783527 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. Yovine A; Riofrio M; Blay JY; Brain E; Alexandre J; Kahatt C; Taamma A; Jimeno J; Martin C; Salhi Y; Cvitkovic E; Misset JL J Clin Oncol; 2004 Mar; 22(5):890-9. PubMed ID: 14990645 [TBL] [Abstract][Full Text] [Related]
18. Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group (GOG). Muss HB; Blessing JA; Eddy GL; McGehee R Invest New Drugs; 1992 Apr; 10(1):25-6. PubMed ID: 1607251 [TBL] [Abstract][Full Text] [Related]
19. Phase I study of echinomycin administered on an intermittent bolus schedule. Harvey JH; McFadden M; Andrews WG; Byrne PJ; Ahlgren JD; Woolley PV Cancer Treat Rep; 1985 Dec; 69(12):1365-8. PubMed ID: 4075312 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT; Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]